Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ISPC files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsiSpecimen approves 2025 stock incentive plan at reconvened annual meeting
Filed May 29, 2026 · Period ending May 29, 2026 · ~1 min read
Key Changes
-
medium
Shareholders approved the 2025 Stock Incentive Plan with 461,073 votes for versus 186,740 against, enabling equity-based compensation grants that may dilute existing shareholders but help retain talent.
Item 5.07 verify on EDGAR → -
low
Arphing (Tommy) Lee elected as Class I director for three-year term expiring 2028, receiving 562,361 votes with 150,431 withheld in routine board election.
Item 5.07 verify on EDGAR → -
low
Bush & Associates CPA LLC ratified as independent auditor for 2025 with strong support (2.4M for vs 155K against) in standard governance vote.
Item 5.07 verify on EDGAR → -
low
Only 35% of eligible shares participated in reconvened annual meeting held May 29, 2026 for fiscal 2025 matters, reflecting low shareholder engagement.
Item 5.07 verify on EDGAR →
Summary
iSpecimen held its reconvened 2025 Annual Meeting on May 29, 2026, where shareholders approved three routine proposals. The most significant was authorization of a new stock incentive plan that will allow the company to grant equity compensation to employees and directors. While this is standard practice for retaining talent, it creates potential dilution for existing shareholders.
The meeting also saw the election of Tommy Lee to a three-year board term and ratification of the company's auditor. Notably, only about 35% of eligible shares participated in the voting, suggesting relatively low shareholder engagement. The 'reconvened' nature of the meeting indicates it was a continuation from an earlier date, likely due to initial quorum or procedural issues. Retail investors should watch for details on the size and terms of the approved stock plan in upcoming proxy materials, as this will determine the extent of potential dilution from future equity grants.
Section-by-Section Diff
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
iSpecimen held its reconvened 2025 Annual Meeting on May 29, 2026, electing one director and approving auditor and stock plan proposals.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
At the reconvened 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of iSpecimen Inc. (the “Company”) on May 29, 2026, of the Company’s 8,478,579 shares of common stock issued and outstanding and eligible to vote as of the record date of November 3, 2025, a quorum of 2,979,059 shares, or approximately 35.14% of the eligible shares, was present or represented by proxy.
The company held its reconvened annual shareholder meeting with approximately 35% of eligible shares participating. This represents a relatively low quorum level, though sufficient for conducting business. The meeting was a continuation from an earlier date, as indicated by the 'reconvened' designation.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 30, 2026 · How we verify